Editorial
Advances in the treatment of pediatric type 1 diabetes
Avances en el tratamiento de la diabetes tipo 1 pediátrica
Raquel Barrio Castellanos
Clínica D-Medical, Madrid, Spain
Read
4600
Timeswas read the article
1629
Total PDF
2971
Total HTML
Share statistics
array:24 [ "pii" => "S2341287921000028" "issn" => "23412879" "doi" => "10.1016/j.anpede.2020.09.004" "estado" => "S300" "fechaPublicacion" => "2021-02-01" "aid" => "2969" "copyright" => "Asociación Española de Pediatría" "copyrightAnyo" => "2020" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "An Pediatr (Barc). 2021;94:65-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S1695403320303805" "issn" => "16954033" "doi" => "10.1016/j.anpedi.2020.09.001" "estado" => "S300" "fechaPublicacion" => "2021-02-01" "aid" => "2969" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "An Pediatr (Barc). 2021;94:65-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Avances en el tratamiento de la diabetes tipo 1 pediátrica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "65" "paginaFinal" => "67" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Advances in the treatment of pediatric type 1 diabetes" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1763 "Ancho" => 2500 "Tamanyo" => 377206 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Tipo de monitorización continua y a demanda de glucosa. Sistema Dexcom; Novalab (A). Sistema Guardian; Medtronic (B). Sistema Eversense; Roche (C). Sistema FreeStyle; Abbott (D). Sistema ciego «Ipro»; Medtronic (E).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Raquel Barrio Castellanos" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Raquel" "apellidos" => "Barrio Castellanos" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2341287921000028" "doi" => "10.1016/j.anpede.2020.09.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287921000028?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403320303805?idApp=UINPBA00005H" "url" => "/16954033/0000009400000002/v2_202102090634/S1695403320303805/v2_202102090634/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S2341287921000016" "issn" => "23412879" "doi" => "10.1016/j.anpede.2020.04.017" "estado" => "S300" "fechaPublicacion" => "2021-02-01" "aid" => "2835" "copyright" => "Asociación Española de Pediatría" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "An Pediatr (Barc). 2021;94:68-74" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Diagnostic accuracy of the tri-ponderal mass index in identifying the unhealthy metabolic obese phenotype in obese patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "68" "paginaFinal" => "74" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Precisión diagnóstica del índice de masa triponderal (kg/m<span class="elsevierStyleSup">3</span>) para identificar el fenotipo de riesgo metabólico en pacientes obesos" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Diego Yeste, María Clemente, Ariadna Campos, Anna Fábregas, Eduard Mogas, Laura Soler, Antonio Carrascosa" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Diego" "apellidos" => "Yeste" ] 1 => array:2 [ "nombre" => "María" "apellidos" => "Clemente" ] 2 => array:2 [ "nombre" => "Ariadna" "apellidos" => "Campos" ] 3 => array:2 [ "nombre" => "Anna" "apellidos" => "Fábregas" ] 4 => array:2 [ "nombre" => "Eduard" "apellidos" => "Mogas" ] 5 => array:2 [ "nombre" => "Laura" "apellidos" => "Soler" ] 6 => array:2 [ "nombre" => "Antonio" "apellidos" => "Carrascosa" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1695403320301491" "doi" => "10.1016/j.anpedi.2020.04.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1695403320301491?idApp=UINPBA00005H" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287921000016?idApp=UINPBA00005H" "url" => "/23412879/0000009400000002/v1_202102100701/S2341287921000016/v1_202102100701/en/main.assets" ] "en" => array:17 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Advances in the treatment of pediatric type 1 diabetes" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "65" "paginaFinal" => "67" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Raquel Barrio Castellanos" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Raquel" "apellidos" => "Barrio Castellanos" "email" => array:1 [ 0 => "rbarriocastellanos@gmail.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Clínica D-Medical, Madrid, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Avances en el tratamiento de la diabetes tipo 1 pediátrica" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1126 "Ancho" => 2083 "Tamanyo" => 161018 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">International continuous glucose monitoring (CGM)-based targets for glycaemic control (adapted from Battelino et al<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a>).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Type 1 diabetes (T1D) is a hyperglycaemic syndrome resulting from the autoimmune destruction of the pancreatic islet beta cells. After diagnosis and treatment initiation, approximately 50% of patients go through what is known as a partial clinical remission phase,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> of variable duration and characterised by partial recovery of function of beta cells and therefore an increased capacity to produce insulin. The longer this phase lasts, the better the short- and long-term prognosis of diabetes, with a decreased risk of severe hyperglycaemia and chronic complications, improved lipid control and an easier control of diabetes in the future. Prolonging this “honeymoon” phase requires good metabolic control, for which an excellent technological tool is currently available that measures interstitial glucose levels, continuous glucose monitoring (CGM), that should be used in every paediatric patient from the moment diabetes is diagnosed. Positive results have also been reported with the use of monoclonal antibodies such as teplizumab, associated with delayed diagnosis of T1D and prolongation of the honeymoon phase.</p><p id="par0010" class="elsevierStylePara elsevierViewall">Without question, the greatest advances in the treatment of T1D made in recent times involve the use of technology combined with ongoing structured/standardised diabetes education, which is essential in improving disease control, adherence to treatment and patient quality of life.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Despite all these advances, the objectives set for the paediatric population by international societies (American Diabetes Association [ADA], International Society for Pediatric and Adolescent Diabetes [ISPAD]) are not being met, and therefore other approaches need to be explored to improve adherence to treatment.</p><p id="par0015" class="elsevierStylePara elsevierViewall">It is clear that use of the novel rapid-acting insulins (Fiasp®, approved by the European Union for use in children aged more than 1 year in September 2019, and Lyumjev™, authorised in the United States in June 2020) currently available for both multiple daily injection (MDI) therapy and insulin pumps can improve postprandial glycaemic control. However, the main advances made in recent decades involve the use of insulin pumps,<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> CGM systems and the combination of both, along with algorithms for automated insulin delivery and automatic insulin delivery suspension, already in use in clinical practice. In addition, wireless download of data to specific platforms, mostly through the cloud, allows sharing patient information with the caregivers (parents, teachers, diabetes specialists) in real time, allowing for more precise adjustments of treatment in everyday life.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Flash glucose monitoring systems, in which data are only shown when the sensor is scanned, and CGM systems provide information of glucose levels at 5-minute intervals and on glucose level trends. These systems have improved considerably in recent years, in both accuracy and precision, and some are factory-calibrated. At present, the data provided by these systems is precise enough to be used instead of capillary glucose measurements to guide clinical decision-making save in special circumstances. Another important advantage offered by technology is that devices are equipped with alarms and alerts to signal the risk of hyperglycaemia or hypoglycaemia, remind the patient of undelivered boluses or warn of pump blockages (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">With the development of CGM, we moved from an era when glycaemic control was based on glycated haemoglobin levels to one in which it is based on CGM parameters, the “time-in-range” era.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a><a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a> presents the international targets, to which glycaemic variability is added through a coefficient of variation, with a percentage of 36% or less used to define stable diabetes.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">The combination of CGM data downloading to the pump and subsequent interpretation with specific algorithms (sensor-augmented insulin pumps [SAPs]) decreases the risk of hypoglycaemia (predictive low-glucose suspend systems, such as the Medtronic MiniMed 640 G or the Tandem Basal-IQ).</p><p id="par0035" class="elsevierStylePara elsevierViewall">At present, automated insulin delivery systems not only adjust insulin delivery to changes in blood glucose, but also provide automatic corrective bolus delivery,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> a type of system known as hybrid closed-loop, as the user is still required to program insulin boluses for meals and make adjustments to the dose for exercise (Medtronic MiniMed 780 G, which received CE Mark approval in June 2020, and Tandem t:slim X2-Control IQ, approved in the United States in 2020 for use in individuals aged more than 6 years).</p><p id="par0040" class="elsevierStylePara elsevierViewall">In the near future, bihormonal closed-loop systems will be available to automatically deliver both insulin and glucagon as needed (iLet, Beta Bionics). Implementation of bihormonal systems was delayed because they required a form of glucagon that would remain stable in solution, which has finally become available (Dasiglucagon). Also, research on new formulations of glucagon led to the development of a powder form of glucagon for nasal delivery (BAQSIMI™, Lilly), approved by the European Union in 2020 for use in children aged more than 4 years, and a solution contained in pre-filled syringes for self-injection available in the United States (Gvoke™ HypoPen) for individuals aged more than 2 years. These new dosage forms constitute advances in the treatment of severe hypoglycaemic episodes, which continue to be a significant problem.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Since most patients are managed with MDI, we ought to highlight the advances offered by the use of technology in smart insulin pens, which provide data on administered doses, times of injection and insulin temperature. Some of these devices work with bolus calculator apps that help calculate doses for meals or blood glucose corrections taking into account the amount of insulin that is still active.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Last of all, we ought to mention the technological advances that have allowed the introduction of telemedicine services and made data sharing possible. Diabetes may be the chronic disease that could benefit most from telemedicine consultations, as demonstrated during the coronavirus 2019 pandemic. Telemedicine visits are not only useful for glycaemic control, but also for health education, psychological support and closer contact between the patient and the diabetes management team, saving time, eliminating travel, decreasing the hours of missed school and work and preventing contagion during outbreaks and pandemics.</p><p id="par0055" class="elsevierStylePara elsevierViewall">To conclude, it is fair to say that while we wait for current research efforts that are mainly focused on T1D prevention, the protection of insulin-producing cells to slow down disease progression and cell-replacement therapy to bear fruit, advances in technology and new insulin formulations will unquestionably continue to contribute to the improvement and optimization of glycaemic control in individuals with T1D.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Funding</span><p id="par0060" class="elsevierStylePara elsevierViewall">This study was not supported by any source of funding.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Conflicts of interest</span><p id="par0065" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Conflicts of interest" ] 2 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2020-08-10" "fechaAceptado" => "2020-09-01" "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Barrio Castellanos R. Avances en el tratamiento de la diabetes tipo 1 pediátrica. An Pediatr (Barc). 2021;94:65–67.</p>" ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1769 "Ancho" => 2500 "Tamanyo" => 284894 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Types of continuous and on-demand glucose monitoring: Dexcom system, Novalab (A); Guardian system, Medtronic (B); Eversense system, Roche (C); FreeStyle system, Abbott (D); iPro blinded monitoring system, Medtronic (E).</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1126 "Ancho" => 2083 "Tamanyo" => 161018 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">International continuous glucose monitoring (CGM)-based targets for glycaemic control (adapted from Battelino et al<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a>).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The remission phase in type 1 diabetes: Changing epidemiology, definitions, and emerging immuno‐metabolic mechanisms" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "T. Tang Zhong" 1 => "R. Tang" 2 => "S. Gong" 3 => "J. Li" 4 => "X. Li" 5 => "Z. Zhou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/dmrr.3207" "Revista" => array:3 [ "tituloSerie" => "Diabetes Metab Res Rev." "fecha" => "2019" "paginaInicial" => "e3207" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estudio de calidad de vida y adherencia al tratamiento en paciente de 2 a 16 años con diabetes mellitus tipo 1 en Andalucía" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Álvarez Casado" 1 => "M.M. Alonso Montejo" 2 => "I. Leiva Gea" 3 => "J.M. Jiménez Hinojosa" 4 => "M.A. Santos Mata" 5 => "F. Macías" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "An Pediatr (Bar)" "fecha" => "2021" "volumen" => "94" "numero" => "1" "paginaInicial" => "75" "paginaFinal" => "81" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Insulin Pump Therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R. Nimri" 1 => "J. Nir" 2 => "M. Phillip" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "American Journal Therapy" "fecha" => "2020" "volumen" => "27" "numero" => "1" "paginaInicial" => "e30" "paginaFinal" => "341" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Battelino" 1 => "Th Danne" 2 => "R. Bergenstal" 3 => "S.A. Amiel" 4 => "R. Beck" 5 => "T. Biester" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dci19-0028" "Revista" => array:7 [ "tituloSerie" => "Diabetes Care" "fecha" => "2019" "volumen" => "42" "numero" => "8" "paginaInicial" => "1593" "paginaFinal" => "1603" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31177185" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L.H. Messer" 1 => "C. Berget" 2 => "G.P. Forlenza" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/dia.2019.0105" "Revista" => array:7 [ "tituloSerie" => "Diabetes Technol Ther" "fecha" => "2019" "volumen" => "21" "numero" => "8" "paginaInicial" => "1" "paginaFinal" => "8" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30575408" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23412879/0000009400000002/v1_202102100701/S2341287921000028/v1_202102100701/en/main.assets" "Apartado" => array:4 [ "identificador" => "25501" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/23412879/0000009400000002/v1_202102100701/S2341287921000028/v1_202102100701/en/main.pdf?idApp=UINPBA00005H&text.app=https://analesdepediatria.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2341287921000028?idApp=UINPBA00005H" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 1 | 6 | 7 |
| 2024 October | 44 | 47 | 91 |
| 2024 September | 44 | 36 | 80 |
| 2024 August | 53 | 56 | 109 |
| 2024 July | 34 | 31 | 65 |
| 2024 June | 50 | 28 | 78 |
| 2024 May | 44 | 37 | 81 |
| 2024 April | 41 | 33 | 74 |
| 2024 March | 41 | 25 | 66 |
| 2024 February | 30 | 28 | 58 |
| 2024 January | 38 | 18 | 56 |
| 2023 December | 42 | 33 | 75 |
| 2023 November | 50 | 36 | 86 |
| 2023 October | 42 | 25 | 67 |
| 2023 September | 47 | 24 | 71 |
| 2023 August | 44 | 17 | 61 |
| 2023 July | 64 | 20 | 84 |
| 2023 June | 39 | 30 | 69 |
| 2023 May | 71 | 33 | 104 |
| 2023 April | 45 | 16 | 61 |
| 2023 March | 60 | 23 | 83 |
| 2023 February | 53 | 16 | 69 |
| 2023 January | 69 | 17 | 86 |
| 2022 December | 83 | 15 | 98 |
| 2022 November | 75 | 36 | 111 |
| 2022 October | 75 | 35 | 110 |
| 2022 September | 102 | 28 | 130 |
| 2022 August | 89 | 65 | 154 |
| 2022 July | 78 | 35 | 113 |
| 2022 June | 90 | 32 | 122 |
| 2022 May | 77 | 43 | 120 |
| 2022 April | 71 | 14 | 85 |
| 2022 March | 90 | 53 | 143 |
| 2022 February | 74 | 31 | 105 |
| 2022 January | 59 | 24 | 83 |
| 2021 December | 58 | 41 | 99 |
| 2021 November | 73 | 38 | 111 |
| 2021 October | 86 | 92 | 178 |
| 2021 September | 79 | 38 | 117 |
| 2021 August | 64 | 46 | 110 |
| 2021 July | 54 | 25 | 79 |
| 2021 June | 72 | 51 | 123 |
| 2021 May | 53 | 38 | 91 |
| 2021 April | 151 | 109 | 260 |
| 2021 March | 82 | 45 | 127 |
| 2021 February | 154 | 42 | 196 |
| 2021 January | 36 | 18 | 54 |
Show all
